Glioblastoma is a universally lethal cancer with a median survival time of approximately 15 months 1 . Despite substantial efforts to define druggable targets, there are no therapeutic options that notably extend the lifespan of patients with glioblastoma. While previous work has largely focused on in vitro cellular models, here we demonstrate a more physiologically relevant approach to target discovery in glioblastoma. We adapted pooled RNA interference (RNAi) screening technology 2-4 for use in orthotopic patientderived xenograft models, creating a high-throughput negativeselection screening platform in a functional in vivo tumour microenvironment. Using this approach, we performed parallel in vivo and in vitro screens and discovered that the chromatin and transcriptional regulators needed for cell survival in vivo are nonoverlapping with those required in vitro. We identified transcription pause-release and elongation factors as one set of in vivo-specific cancer dependencies, and determined that these factors are necessary for enhancer-mediated transcriptional adaptations that enable cells to survive the tumour microenvironment. Our lead hit, JMJD6, mediates the upregulation of in vivo stress and stimulus response pathways through enhancer-mediated transcriptional pause-release, promoting cell survival specifically in vivo. Targeting JMJD6 or other identified elongation factors extends survival in orthotopic xenograft mouse models, suggesting that targeting transcription elongation machinery may be an effective therapeutic strategy for glioblastoma. More broadly, this study demonstrates the power of in vivo phenotypic screening to identify new classes of 'cancer dependencies' not identified by previous in vitro approaches, and could supply new opportunities for therapeutic intervention.
Glioblastoma is a universally lethal cancer with a median survival time of approximately 15 months 1 . Despite substantial efforts to define druggable targets, there are no therapeutic options that notably extend the lifespan of patients with glioblastoma. While previous work has largely focused on in vitro cellular models, here we demonstrate a more physiologically relevant approach to target discovery in glioblastoma. We adapted pooled RNA interference (RNAi) screening technology 2-4 for use in orthotopic patientderived xenograft models, creating a high-throughput negativeselection screening platform in a functional in vivo tumour microenvironment. Using this approach, we performed parallel in vivo and in vitro screens and discovered that the chromatin and transcriptional regulators needed for cell survival in vivo are nonoverlapping with those required in vitro. We identified transcription pause-release and elongation factors as one set of in vivo-specific cancer dependencies, and determined that these factors are necessary for enhancer-mediated transcriptional adaptations that enable cells to survive the tumour microenvironment. Our lead hit, JMJD6, mediates the upregulation of in vivo stress and stimulus response pathways through enhancer-mediated transcriptional pause-release, promoting cell survival specifically in vivo. Targeting JMJD6 or other identified elongation factors extends survival in orthotopic xenograft mouse models, suggesting that targeting transcription elongation machinery may be an effective therapeutic strategy for glioblastoma. More broadly, this study demonstrates the power of in vivo phenotypic screening to identify new classes of 'cancer dependencies' not identified by previous in vitro approaches, and could supply new opportunities for therapeutic intervention.
Chromatin regulators have emerged as a promising class of druggable targets for cancer therapy 3, 5, 6 . Chromatin regulation is often contextspecific [7] [8] [9] [10] [11] , suggesting that the microenvironment mediates cancer cell response to inhibition of specific chromatin regulators. Therefore, we developed an in vivo RNAi screening strategy to enable the identification of chromatin regulators that are crucial for the survival of glioblastoma cells within a functional tumour microenvironment ( Fig. 1a ). Using an advanced short hairpin RNA (shRNA) delivery vector [2] [3] [4] (Extended Data Fig. 1a-c) , glioblastoma patient-derived xenograft (PDX) cells ( Supplementary Table 1 ) were transduced with a pooled library containing 1,586 inducible shRNAs targeting 406 known chromatin and transcriptional regulators (2-4 shRNAs per gene) and controls, at efficiencies to achieve a single retroviral integration per cell. Transduced cells were selected by a constitutive green fluorescent reporter using fluorescence activated cell sorting (FACS) and used in concurrent in vivo and in vitro screens. In each screen, transduced cells were split into an induced arm and an uninduced control arm. Cells in the induced arm were treated with doxycycline, which induced shRNA expression and a second fluorescent reporter, dsRED. After 3 weeks, induced cells (dsRED + ) or uninduced control cells were sequenced and shRNA representation was quantified. For the in vivo screen, 61 mice were implanted with cells and randomly assigned to the control or induced arm. Multiple mice were grouped as single biological replicates, providing the fold coverage necessary to obtain reproducible results (Extended Data Fig. 2a ), and enabling successful in vivo negativeselection screening in a solid tumour model (see Methods).
Genes crucial for glioblastoma cell survival were prioritized by calculating depletion scores for each shRNA, based on the decrease in shRNA frequency in the induced arm compared to the uninduced control arm. Positive hits were defined as expressed genes that were targets of at least two non-overlapping shRNAs that effectively mediated cellular depletion ( Fig. 1b and Supplementary Table 2 ). In vivo hits outnumbered the in vitro hits and, surprisingly, there was almost no overlap between hits that caused cell depletion in vitro versus in vivo (Fig. 1c) . Genes that caused cell depletion in both screens were restricted to the positive-control gene RPA3 (Extended Data Fig. 2b ) and two genes essential for transcription and maintenance of DNA methylation, POLR2B and DNMT1. Differences in molecular dependencies were not explained by expression of the hits, as there were no significant differences in the in vivo expression of the hits compared to their in vitro expression (Extended Data Fig. 3a, b ). Collectively, these primary screen results reveal unique molecular dependencies for glioblastoma cells in vivo.
Gene Ontology analysis of the hits revealed significantly enriched molecular classes that were microenvironment-specific. In vitrospecific hits were enriched for genes that promote cellular metabolism and macromolecule biogenesis, whereas in vivo-specific hits were enriched for genes controlling transcriptional elongation ( Fig. 1d and Extended Data Fig. 3c, d) . Nearly all mediators of transcriptional pause-release and elongation included in the screen scored as in vivo-specific hits, including recently annotated regulators, jumonji C-domain-containing protein 6 (JMJD6) 12 , the DOT1 like histone lysine methyltransferase (DOT1L) complex 13 , and ring finger protein 20 (RNF20) 14 (Fig. 1e ). Several primary hits were validated in secondary in vivo survival assays (Extended Data Fig. 3e-h To investigate the mechanisms underlying the selective dependency of glioblastoma cells on transcriptional pause-release and elongation in vivo, we derived and analysed global transcriptional and chromatin landscapes from cells grown in both the intracranial and cell culture environments ( Fig. 2a ). Multiple PDX models representing different molecular glioblastoma subtypes from our laboratory were included in the analysis ( Supplementary Table 1 ), as were data generated by an independent laboratory 15 . Gene expression profiles were markedly different when cells were grown concurrently for around 3 weeks in an intracranial xenograft model as compared to cell culture conditions (Extended Data Fig. 4a, b and Supplementary Table 3 ).
Gene set enrichment analysis (GSEA) 16 coupled to Enrichment Map 17 visualization was used to annotate differentially enriched biological pathways (Fig. 2b , c, Extended Data Fig. 4 and Supplementary  Table 4a -f). Cancer cells cultured in serum-free conditions, in which nutrients and space are in abundant supply, were enriched for transcriptional programs of proliferation. By contrast, transcriptional programs associated with stress response, signalling response and other stimulus response pathways were enriched in intracranial tumours, in which nutrients and space are less abundant. The stimulus response pathways upregulated in the intracranial tumour environment include GSC  GSC GSC  GSC  GSC   GSC  GSC   GSC  GSC  GSC  GSC  GSC   GSC 26 . The score increases with depletion. Boxes indicate target gene 'hits' that caused depletion of the cell population when inhibited. c, Venn diagram of hits from each screen. d, Enrichment of hits in Gene Ontology (GO) gene sets, using the screened library gene list as a background to control for bias towards chromatin modifiers. Significance was calculated by Benjamini-Hochberg false discovery rate (FDR). e, Schematic of transcription elongation machinery, highlighting in vivo-specific hits. TFs, transcription factors; TSS, transcription start site. Node size represents the number of genes overlapped. c, Representative GSEA enrichment plots. FDR calculated by GSEA software. d, Principle component analysis of matched glioblastoma (GBM) cells in primary tumours, intracranial (IC) tumours and cell culture. NSC, neural stem cells. e, Fold change of the H3K27ac signal at enhancers of genes with a greater than 2.5-fold change in mRNA expression between conditions, or a 0.9-1.1-fold change (stable genes). P values were determined by two-sided Mann-Whitney U-test. RPKM, reads per kilobase per million. pause-controlled pathways consisting of genes with a strong reliance on transcription pause-release and elongation for their expression 13, [18] [19] [20] [21] [22] . Of the 55 genes that were upregulated more than 2.5-fold in tumour cells grown intracranially in both the proneural GBM528 and mesenchymal GBM3565 models, many were important transcription factors and signalling molecules regulated by polymerase II (Pol II) pausing, including pause-controlled genes, such as EGR1 and FOS 13, 23 (Extended Data Fig. 5a -c). These 55 genes were also highly expressed in tumours from patients with primary glioblastoma (Extended Data Fig. 5d , e). Principal component analysis of the expression profiles of matched primary tumours and derived models revealed that cells grown as intracranial tumours more accurately modelled the transcriptome of the primary patient tumour from which they were derived, as compared with cells grown in culture ( Fig. 2d ). Collectively, these data suggest that the upregulated pause-controlled gene programs that occur in vivo may allow the tumour cells to interact with and adapt to their complex microenvironment, supporting their increased dependency on transcription pause-release and elongation factors for in vivo survival.
Enhancers act together with transcription factors to drive transcriptional changes through transcriptional pause-release and elongation. Leveraging chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) of the dynamic enhancer mark Lys27 acetylation of histone 3 (H3K27ac), transcriptional changes in tumour cells grown intracranially were reflective of genome-wide alterations in enhancers in two glioblastoma models ( Fig. 2e ). Nearly 20% of all enhancer elements, including 'super-enhancer' loci, were condition-specific, and expression of their putative target genes, as determined by the nearest expressed gene, corresponded to the condition-dependent changes in the enhancer signal (Extended Data Fig. 6 and Supplementary Table 5 ). Together, these data show that the microenvironment regulates the epigenome to transform the glioblastoma cell state by differentially activating enhancers and their target genes.
Of the in vivo-specific hits, we prioritized the 12 genes encoding transcription elongation factors for further consideration as therapeutic targets. Using large, independent datasets of primary patient tumours, we correlated expression of each of the 12 transcription elongation factors with the expression of the 55 genes that were consistently upregulated in vivo across both PDX tumour models, which we hypothesized are main drivers of the transcriptional programs needed by tumours to adapt and survive in the stressful and dynamic in vivo micro environment. JMJD6 was the most positively correlated hit across all datasets, including the Ivy Glioblastoma Atlas Project (Ivy GAP) dataset, which provides intratumour microenvironmentspecific expression 24 ( Fig. 3a and Extended Data Fig. 7a-d ), suggesting JMJD6 regulates many of the genes that are important for the survival of glioblastoma cells in vivo.
To assess further the regulatory role of JMJD6 in patient tumours, we correlated the expression of all genes in The Cancer Genome Atlas (TCGA) glioblastoma tumours individually with the expression of JMJD6 (Extended Data Fig. 7e and Supplementary Table 6 ). Genes positively correlated with JMJD6 were enriched in pause-controlled programs, similar to those upregulated in intracranial tumours, whereas genes negatively correlated with JMJD6 were enriched in metabolic programs, similar to those upregulated in cell culture (Extended Data Fig. 7f and Supplementary Table 4g ). These findings indicate a potential mechanism for the in vivo specificity of JMJD6 in the screen, and provide evidence that JMJD6 may control transcriptional pause-release in primary glioblastoma tumours.
To explore the clinical significance of JMJD6, we analysed gene expression in primary tumours and found that both JMJD6 mRNA ( Fig. 3b ) and protein ( Fig. 3c and Extended Data Fig. 7g ) were highly expressed in gliomas, and increased with tumour grade. These data, along with the robust in vivo depletion of tumour cells harbouring JMJD6 shRNA in the primary screen (Extended Data Fig. 7h ), provide further evidence that JMJD6 constitutes a strong lead target for further evaluation.
In HEK293T and HeLa cells, JMJD6 acts with bromodomain containing 4 (BRD4) as a key activator of enhancer-mediated pause-release at genes controlled by Pol II pausing 12 (Extended Data Fig. 8a ). To determine whether JMJD6 localizes to enhancers in glioblastoma in vivo, we performed JMJD6 ChIP-seq of tumour cells in intracranial tumours. Globally, JMJD6 was distributed throughout the genome, but was strongly enriched at enhancers and promoters (Extended Data Fig. 8b , c and Fig. 3d ). Furthermore, in the PDX models, target genes of JMJD6-bound enhancers were enriched for genes upregulated in vivo (Extended Data Fig. 8d, e ) and for genes that positively correlated with JMJD6 in primary patient tumours (Extended Data Fig. 8f, g) .
These results indicate that JMJD6 may regulate the expression of genes targeted by JMJD6-bound enhancers through enhancer-mediated pause-release, both in the intracranial tumour environment in our PDX models, as well as in patient tumours.
To investigate, we conducted ChIP-seq of RNA Pol II in GBM528 and GBM3565 cells both in vivo and in vitro. Transcription pause-release and elongation was measured by the pausing index, which is the ratio of the Pol II density surrounding the transcriptional start sites to the density of Pol II over the gene body 22 . The higher the pausing index, the more paused the gene transcript. Genes that were consistently upregulated in vivo in both PDX tumours models, such as EGR1, were transcriptionally paused in vitro and released in vivo ( Fig. 3e and Extended Data Fig. 8h , i). To interrogate globally whether JMJD6 activity at enhancers promotes pause-release in vivo, we calculated the in vivo pausing index for all expressed genes with or without enhancers. Genes regulated by JMJD6-bound enhancers had lower pausing indexes, or increased levels of pause-release activity, compared to genes regulated by enhancers not bound by JMJD6 ( Fig. 3f ). This effect was specific to JMJD6 binding at enhancers, as genes bound by JMJD6 at locations other than an enhancer did not demonstrate increased pause-release.
We then evaluated the activity of JMJD6-bound enhancers relative to enhancers not bound by JMJD6 in vivo. Building upon recent evidence that active enhancers are transcribed and that activity can be estimated by RNA Pol II binding 25 , we measured relative RNA Pol II binding at JMJD6-bound enhancers versus enhancers not bound by JMJD6, and found that JMJD6-bound enhancers had significantly higher levels of Pol II binding ( Fig. 3g ). Measurements of Pol II binding at JMJD6 sites, including outside of enhancers, revealed that Pol II binding was highest at JMJD6-bound enhancers. Collectively, these data provide evidence that JMJD6 binding is associated with increased enhancer activity and promotes pause-release in human glioblastoma cells within the tumour microenvironment.
We next sought to determine the potential preclinical value of JMJD6 as a therapeutic target. Targeting JMJD6 with an inducible shRNA distinct from the primary screen again did not alter glioblastoma cell growth or survival in vitro, but did extend survival in an orthotopic xenograft mouse model (Extended Data Fig. 9a-c ). Furthermore, the inducible shRNA transgene was silenced in tumours that grew in the knockdown arm (Extended Data Fig. 9d ), suggesting that achieving sustained JMJD6 inhibition may provide an even more notable therapeutic benefit.
These data prompted us to use CRISPR-Cas9 technology to create multiple clonal populations of glioblastoma cells in vitro in which JMJD6 expression was completely knocked out by expression of one of two independent single-guide RNAs (sgRNAs) (Fig. 4a ). Glioblastoma cells lacking JMJD6 formed clonal populations and proliferated with little or no growth defect in vitro when compared to non-targeting sgRNA control cell populations ( Fig. 4b ). However, mice bearing JMJD6-deficient cells showed a notable survival advantage compared to mice with control cells implanted, with over 25% of mice in the JMJD6-deficient group being tumour-free after 100 days ( Fig. 4c ). Similar results were found using an independent PDX model (Extended Data Fig. 9e-g) .
To validate other screen hits using in vivo survival studies, we performed similar experiments targeting DOT1L, a recently discovered mediator of transcription elongation 13 and top scoring hit from the primary screen, and DPY30, another top scoring hit from the primary screen that is not known to be involved in transcription pause-release or elongation. Constitutive shRNA-mediated knockdown of these genes in glioblastoma cells from three independent PDX models caused no proliferation defect in vitro (Fig. 4d , e and Extended Data Fig. 9h-q) . However, mice bearing cells with knockdown of DOT1L or DPY30 survived significantly longer than mice implanted with cells expressing non-targeting shRNAs ( Fig. 4f and Extended Data Fig. 9r -v). These results further demonstrate the power of in vivo screening to identify in vivo-specific cancer dependencies, and indicate that many of the identified hits from the primary screen are strong candidates for future investigation as potential therapeutic targets in glioblastoma.
Pharmaceutical approaches to cancer drug discovery typically involve high-throughput screening of established cell lines cultured in vitro to reveal individual targetable oncogenes that predominantly regulate cancer cell proliferation. However, drugs developed to modulate these targets have thus far achieved limited success in patients, especially for glioblastoma. This therapeutic roadblock prompted us to develop and validate a new in vivo functional screening strategy for glioblastoma that recapitulates most stressors and stimuli of the tumour microenvironment. Our approach revealed several in vivo-specific biological targets for glioblastoma, including JMJD6, indicating that cancer cells are dependent on unique molecular effectors for growth and survival depending on the extrinsic factors in their microenvironment. Specifically, we found that glioblastoma cells in vivo, but not in vitro, were dependent on Pol II pause-release and transcription elongation machinery for survival (Extended Data Fig. 10 ). This machinery is necessary to upregulate pause-controlled stress and signalling response pathways that promote cell survival 13, 18, 20, 21 . This finding unexpectedly revealed that in the primary tumour, targeting the microenvironment-induced stress response mechanisms of the cancer cell may be a more effective therapeutic strategy than targeting cell growth, the main target of traditional chemotherapies. Overall, our results demonstrate feasibility for direct target identification in vivo in solid tumours and suggest new avenues for therapeutic development.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Human glioblastoma specimen culture conditions. All human glioblastoma tissues were obtained from excess surgical materials from consented patients after review from a neuropathologist and used in accordance with an approved protocol by the Institutional Review Board at Cleveland Clinic. As previously described 27 , glioblastoma cells were derived immediately after dissociation of primary patient tumour or after transient xenograft passage. For all in vitro studies, glioblastoma cells were cultured in Neurobasal medium (Gibco) with B27 (without vitamin A, ThermoFisher), basic fibroblast growth factor (20 ng ml −1 , R&D) and epidermal growth factor (20 ng ml −1 , R&D).
Primary glioblastoma models were validated to be unique by short-tandem repeat analysis at multiple xenograft passage numbers (analysis conducted by ATCC and Duke University, Cell Line Authentication Service). Short-tandem repeat results are available upon request. All cells used were derived from primary patient tissues, and are not included in the database of commonly misidentified cell lines maintained by the ICLAC. All cell lines are routinely tested for mycoplasma contamination and were negative. Patient-derived orthotopic xenografts. All animal procedures were performed in accordance with Cleveland Clinic Institutional Animal Care and Use Committee (IACUC) approved protocols. For intracranial tumours, size cannot be measured directly. Therefore, specific neurological signs indicating the presence of brain tumours (such as seizures, ataxia and lethargy) are monitored, in accordance with the IACUC approved protocol, and mice were always euthanized when these signs became present. The number of animals included in each of the described studies was based on extensive past experience in the development and use of glioblastoma xenograft models by our group. Each study was designed to minimize unnecessary animal use, optimize statistical power, and account for known variance in each model system. For all in vivo experiments, human glioblastoma cells were intracranially implanted into non-obese diabetic-severe combined immunodeficient (NOD-SCID) Il2rg −/− mice (NSG; JAX Charles River) mice at 4-6 weeks of age. Within this age window, mice were age-matched across groups. For the primary screen, mice were randomized by cage into control or induced group. The xenograft implantations were performed blinded to group. Researchers were not blinded during the rest of the experiment as no subjective measurements were used. In total, 31 female mice and 30 male mice were used in the screen, with an even split between control and induced populations. For individual shRNA or CRISPR survival analysis, xenograft implantations were performed blinded to group, and the gender of the mice in a given study were kept identical to maintain consistency across experimental and control groups. See individual methods for number and gender of mice used. Mice were euthanized at the onset of neurological signs, and tumours were removed for further analysis. In vivo and in vitro inducible shRNA screens. To investigate the effects of targeting epigenetic regulators in glioblastoma cells within the tumour microenvironment, we modified an inducible in vivo RNAi screening system, previously used for screening in haematological malignancies 2,3 , for use in solid tumours (Fig. 1a ). The advanced inducible shRNA delivery vector has high fidelity expression and dual fluorescent reporters to reduce the noise and bias that weaken traditional shRNA screens 2,4 (Extended Data Fig. 1a-c ). Our shRNA library contained 1,586 shRNAs targeting 406 known chromatin and transcriptional regulator genes (2-4 shRNAs per gene), with positive and negative control shRNAs.
Well-characterized, PDX glioblastoma cells ( Supplementary Table 1 ) were transduced with the shRNA library pool such and cells with genomic integration of shRNAs, as monitored by expression of a constitutive green fluorescent reporter, were selected using FACS. With the selected pool of cells, we performed an in vitro screen in previously defined serum-free cell culture conditions 15 concurrent with an in vivo screen in intracranial mouse xenografts. Each screen used the same population of cells distributed across two arms: (1) control, in which cells were left uninduced (no shRNA expression); and (2) experimental, in which cells were treated with doxycycline to induce shRNA expression. Induction also led to expression of a second fluorescent reporter, dsRED, which allowed isolation of cells actively expressing an shRNA at the endpoint of the screen (Fig. 1a and Extended Data Fig. 1a, b) . The in vitro screen consisted of three independent replicates per arm, and cells were collected after 3 weeks. In the parallel in vivo screen, single animals could not be used as independent replicates as the maximum number of engrafted cells per animal provided insufficient fold coverage of the shRNA library. Therefore, 61 mice were implanted with cells and randomly assigned to the control (20 mice) or induced arm (41 mice). Multiple mice were then grouped together as a single biological replicate in order obtain three independent replicates for the induced arm and two for the uninduced arm. This provided the fold coverage necessary to obtain reproducible results (Extended Data Fig. 2a ), and enabled successful in vivo negative-selection screening in a solid tumour model. Tumours developed for 2-3 weeks until mice exhibited signs of neurological dysfunction. Mice were then euthanized, tumours were excised and dissociated, and uninduced or induced tumour cells from the control or experimental arms, respectively, were collected by FACS. The representation of shRNAs from each cell population was quantified by high depth sequencing of lentivirally integrated shRNA barcodes.
For both screens, genes crucial for glioblastoma cell survival were prioritized by calculating depletion scores for each shRNA, based on the decrease in shRNA frequency in the induced arm compared to the uninduced control arm. Positive hits were defined as expressed genes that were targets of at least two non-overlapping shRNAs that effectively mediated cellular depletion (Fig. 1b, c and Supplementary  Table 2 ). shRNA library generation. An all-in-one inducible retroviral vector with an optimized 'miR-E' shRNA design (RT3REVIR) 4 was used to deliver shRNAs. In brief, this construct contains an optimized third-generation Tet-responsive element and rtTA3 to potentiate a positive-feedback loop upon addition of doxycycline, enhancing expression of the construct upon induction and reducing construct leakiness. It also contains an enhanced design of the miR30 backbone to allow for more efficient shRNA processing. In addition, the second reporter is inducible and is expressed in conjunction with the shRNA, which allows for selection of cells actively expressing an shRNA at the time of collection, and markedly reduces the number of cells included in the final analysis that contained silenced shRNAs.
We shuttled the library of 1,568 shRNAs (shERWOOD Epigenetics-related genes library, transOMIC) into the RT3REVIR vector using previously published methods 4 . To produce virus, retroviral plasmid library was transfected into HEK293T Phoenix packaging cells as previously described 2 . Chloroquine (25 μ M, Sigma-Aldrich) was added to enhance plasmid stability. Functional screening assays. Approximately 60 million patient-derived glioblastoma cells were transduced with the pooled inducible shRNA library at 1.1% transduction efficiency to ensure that cells were transduced with only 1 shRNA per cell. Protamine sulfate (Sigma-Aldrich) was used for transduction. Successfully transduced cells were selected by a constitutive Venus fluorescent reporter using FACS. Cells were allowed to recover and expand for three passages. The same population of cells was used simultaneously for a screen completed in triplicate in standard serum-free cell culture conditions and for a screen completed in an in vivo intracranial xenograft mouse model.
For the in vivo screen, each mouse was intracranially injected with 500,000 cells to maximize the number of engrafted cells per mouse. Fold coverage of the shRNA library is determined by the number of engrafted cells (not number implanted). On the basis of GFP spike-in dilution assays, we estimated between 10 and 20% of cells implanted are engrafted (50,000-100,000 cells per mouse). To overcome this issue of low-fold coverage when using a single animal, typically the limiting factor when screening in solid tumours in vivo, we injected 61 mice and randomly assigned them to the induced arm (41 mice) or the control arm (20 mice). Mice in the induced arm were maintained on doxycycline containing water (2 mg ml −1 doxycycline and 2% sucrose, Sigma-Aldrich) for the duration of the screen. Cells were not exposed to doxycycline before being injected into the mouse, allowing us to screen for factors important for tumour growth rather than engraftment efficiency. When a mouse began to show overt neurological signs, which occurred between 2 and 3 weeks, it was euthanized, the tumour was collected, macroscopically dissected, dissociated to single cells (Tumour Dissociation Kit, human and GentleMACS Octo Dissociator with Heaters, Miltenyi Biotech) and depleted of any remaining mouse cells using magnetic-activated cell sorting (Mouse Cell Depletion Kit, Miltenyi Biotech). Each mouse was processed independently. Tumour cells from the mice in the induced arm were sorted by FACS to collect Venus + dsRED + cells (denoting shRNA expression). The average number of double-positive cells collected across 41 mice was 229,964 (range: 12,440-758,143 cells). 26 out of 41 mice had greater than 100,000 cells collected (see Source Data). Mice were combined after sequencing into 'biological replicate' groups of 13-14 mice (see Source Data), which provided, on average, about 3 million cells per biological replicate or 'n' . This represented a fold coverage of approximately 2,000 per replicate. Tumour cells from mice in the uninduced control arm were sorted by FACS to collect Venus + dsRED − cells (shRNA integrated but not expressed). The average number of single-positive control cells collected across 20 mice was 851,916 (range: 144,184-1.8 million cells). 16 out of 20 mice had over 500,000 cells collected. Control mice were combined after sequencing into two biological replicate groups of 10 mice (see Source Data), which provided on average about 8 million cells per 'n' . This represented a fold coverage of approximately 5,000 per replicate. The baseline induction rate of the inducible system in vivo is 30-40%, which limits the number of cells that can be collected from mice in the induced arm compared to the control arm (from which we collected all cells). For this reason, we used more than double the number of mice in the induction arm compared to the control arm to obtain similar fold coverage rates.
For the in vitro screen, 1.5 million cells were placed in serum-free sphere culture in a 15 cm plate for each replicate. Three replicates were used for the induced arm and three replicates were used for the control arm. Doxycycline (1 μ g ml −1 , Sigma-Aldrich) was added to cells in the induced arm at time of plating and cells were maintained on doxycycline for 21 days, which is the same amount of time that the last of the intracranial tumours were collected for the in vivo screen. Cells in the uninduced control arm were also maintained for 21 days in culture with no doxycycline. Cells had a doubling time of 1.5 days and were passaged every 3-4 days to prevent cells from becoming over-confluent. During passage, at least 2 million cells were re-seeded in the plate to maintain library representation. At the conclusion of the screen Venus + dsRED + cells (1.5 million for each replicate) were collected by FACS from the induced arm, while Venus + dsRED − cells (1.5 million for each replicate) were collected by FACS for the undinduced arm. shRNA amplification and sequencing. Each mouse was processed and analysed separately. Genomic DNA was isolated and sequenced as described 2 with slight modification. Genomic DNA was isolated by two rounds of phenol extraction using PhaseLock tubes (5prime) followed by isopropanol precipitation. Deep sequencing libraries were generated by PCR amplification of shRNA guide strands using barcoded primers that tag the product with standard Illumina adapters (p7+ loop, 5′-CAAGCAGAAGACGGCATACGA-NNNN (4 nucleotide barcode)-TAGTGAAGCCACAGATGTA-3′; p5+ miR3′, 5′-AATGAT ACGGCGACCACCGATGGATGTGGAATGTGTGCGAGG-3′). Libraries were sequenced on the HiSeq 2500 platform at the Cleveland Clinic Genomics Core Facility. Libraries were sequenced using a primer that reads in reverse into the guide strand (miR30EcoRISeq, 5′-TAGCCCCTTGAATTCCGAGG CAGTAGGCA-3′). Sequencing analysis and shRNA scoring. Sequence processing was performed using two custom workflows at https://usegalaxy.org 28 . Annotated workflows are stored in the https://usegalaxy.org published workflows repository and can be accessed and used using the following links: Workflow 1: https://usegalaxy.org/u/ tyleremiller/w/shrna-pipeline1. It is used first to generate an output needed for workflow 2. Workflow 2: https://usegalaxy.org/u/tyleremiller/w/shrnastep2. Raw read counts were converted to reads per million (RPM) to control for variations in total shRNA reads in each sample.
Results from multiple mice were randomly pooled together to form replicates (n = 3 for the induced arm, with each replicate containing 13-14 mice, while n = 2 for the control arm, with each replicate containing 10 mice). To provide a sufficient baseline for detecting shRNA depletion (negative selection) in experimental samples, we aimed to acquire an average of more than 1,000 reads per shRNA in each replicate, which would require 1.6 × 10 6 reads per replicate. In practice, we achieved over 1.5 × 10 7 reads for all replicates (nearly 10,000-fold coverage). Pooling the mice was essential for achieving proper fold coverage and highly correlated replicates. The average correlation score between individual mice from the induced groups was R = 0.24, while the average correlation value between the three combined replicates was R = 0.80.
shRNAs were scored using RIGER, and extension of the GENE-E package (Broad Institute) 26 . Median RPM value for each replicate was used for analysis. The signal-to-noise ratio of replicates was used to calculate individual shRNA score based on their ability to deplete cells in the induced arm compared to the control arm and second-best shRNA score was used to rank genes. Expressed genes with a RIGER depletion score ≥ 2 were considered hits. Gene Ontology enrichment analysis and visualization. Gene Ontology analysis for screen hits (Fig. 1 and Extended Data Fig. 3 ) was conducted using background correction to understand what was enriched above what would be expected for a list comprised of chromatin modifiers. Specifically, the gene list of in vivo or in vitro hits was imported into gProfiler 29 to generate enrichment scores for all Gene Ontology gene sets according to recommended settings for gProfiler (http://baderlab.org/Software/EnrichmentMap/GProfilerTutorial), with the exception that we used the full list of genes included in the screen as a background list ('Gene list as a stat. background' feature) to control for bias towards chromatin modifiers. Analysis when starting with whole transcriptome data. For Gene Ontology analysis when analysing whole transcriptome data ( Fig. 2 and Extended Data Fig. 4 ), data were imported into GSEA 16 software to generate enrichment scores for gene sets in Hallmark, C2.all and C5.all MSigDB datasets. Exact settings are listed in Supplementary Table 4 . Cytoscape (v3.2.1) and the Enrichment Map 17 plug-in was used to generate networks for gene sets enriched with a FDR cut-off of < 0.05. For GSEA analysis in Extended Data Fig. 7 , ranked lists were generated from whole transcriptome expression data of GBM528 or GBM3565 cells grown in vivo versus in vitro (for Extended Data Fig. 8d, e ), or from the correlations of genes with JMJD6 in glioblastoma tumours from the TCGA database (for Extended Data Fig. 8f, g) . These ranked lists were run against a gene set consisting of genes targeted by JMJD6-bound enhancers in GBM528 or GBM3565 cells. Normalized enrichment scores and FDR values were generated by GSEA software. Global characterization of glioblastoma cells grown in vivo and in vitro. To characterize the cell state of human tumour cells grown in vivo and compare it to those grown in culture, we used the same experimental setup as was done in the screen (schematic in Fig. 2a ). We took patient-derived glioblastoma cells growing in vitro and split them in half. We injected half into 20 mice per glioblastoma model and maintained the other half in culture in independently maintained replicates. Multiple PDX models representing different molecular glioblastoma subtypes were included in the analysis, including our primary screen model, the proneural model GBM528, and the mesenchymal model GBM3565 ( Supplementary Table 1 ). We also analysed data obtained from an independent laboratory from two other PDX models, GBM1228 and GBM0308, which were grown similarly in vivo and in vitro 15 . In addition, these two models had matched data from the corresponding primary tumour 15 . For the in vivo arm, each mouse was intracranially implanted with 500,000 cells. When a mouse began to show overt neurological signs, which occurred between 2 and 3 weeks, it was euthanized, the tumour was collected. macroscopically dissected, dissociated to single cells (Tumour Dissociation Kit, human and GentleMACS Octo Dissociator with Heaters, Miltenyi Biotech) and depleted of any remaining mouse cells using magnetic-activated cell sorting (Mouse Cell Depletion Kit, Miltenyi Biotech). We used two rounds of mouse cell depletion to ensure only human tumour cells were used in the analysis. We were consistently able to obtain greater than 98% purity of human cells with this method. Each mouse was processed independently. For RNA-seq samples, cells from 2-3 mice were pooled together to form each replicate. For ChIP-seq samples, many mice were pooled together for ChIP-seq as cell number was a limiting factor. Cells grown in culture were maintained for 3 weeks and then harvested for RNA-seq and ChIP-seq. RNA-seq. RNA was extracted from human glioblastoma cells with TRIzol (ThermoFisher), separated using Phase Lock Gel tubes (5 Prime), and purified using the miRNAeasy kit (Qiagen) according to the manufacturer's protocol. Total RNA was prepared for sequencing by Beckman- Coulter however, all FPKM values provided are those calculated by Cufflinks. To generate an expressed genes list, an average of replicates for each condition was calculated and genes with FPKM values greater than 0.25 in either intracranial sample or culture sample were considered expressed. Genes that did not meet this expression cut-off (replicate average FPKM < 0.25 in intracranial and culture conditions) were removed as not expressed. Expressed genes were tabled by converting FPKM values < 0.25 to 0.25. Exome sequencing. DNA was collected from GBM528, GBM3565 and GBMcw1919 cells using standard techniques. The Case Genomics Core processed the DNA using the Illumina Nextera Rapid Capture Exome kit and sequenced on the Illumina HiSeq 2500 platform at greater than 100× coverage. Data were processed by the Case Genomics Core to generate variant call format (VCF) files, and clinical variant calls were made using Omicia Opal Software (http://www. omicia.com/). ChIP-seq. ChIP was performed as previously described 32 . For histone modification and transcription factor ChIP-seq, 2 million cells (H3K27ac), 15-20 million cells (JMJD6), or 5 million cells (Pol2) were crosslinked in PBS plus 1% fresh formaldehyde for 10 min at 25 °C, quenched for 5 min with 125 mM glycine, washed twice in cold PBS with protease inhibitors (complete PI, Roche), and stored at − 80 °C. In brief, formaldehyde-fixed cells were lysed and sheared (Branson S220) on wet ice. The sheared chromatin was cleared and incubated overnight at 4 °C with the following antibodies: H3K27ac (Active Motif, 39133), JMJD6 (Abcam, ab64575, lot GR54735-1), and total Pol II (Santa Cruz, sc-899-X, lot H0510). Antibody-chromatin complexes were immunoprecipitated with protein G magnetic Dynal beads (Life Technologies), washed, eluted, reverse crosslinked and treated with RNase A followed by proteinase K. ChIP DNA was purified using Ampure XP beads (Beckmann Coulter) and then used to prepare sequencing libraries for sequencing with the Next-Seq Illumina genome analyser. Peak calling. Reads were aligned to hg19 using Burrows-Wheeler Aligner (BWA) 33 and identical ChIP-seq sequence reads were collapsed to a single read to avoid PCR duplicates. Peaks were called using HOMER 34 v.4.6 using matched inputs with the following parameters: H3K27ac, -histone -tagThreshold 50 was used for enhancer analysis. JMJD6, -factor. Enhancer landscape analysis. To generate enhancer loci lists for each condition, H3K27ac ChIP-seq peak files were filtered to remove all peaks overlapping Letter reSeArCH ENCODE blacklisted regions for functional genomics analysis (https://sites.google. com/site/anshulkundaje/projects/blacklists) as well as peaks with any overlap occurring within ± 1 kb from transcription start sites of all annotated RefSeq genes to exclude promoters. To call target genes of enhancers, enhancer loci were mapped to the nearest expressed gene within the glioblastoma cells. An expressed gene had to be within 200 kb for an enhancer loci to be mapped to a gene. The expressed gene list was the same as described in the RNA-seq methods section above. Peaks were visualized with the Integrative Genomics Viewer (IGV, Broad Institute). Condition-specific enhancers. H3K27ac ChIP-seq enhancer lists from in vivo intracranial xenograft and in vitro cultured cells were merged to create a single peak file. RPKM values within merged peaks were calculated. In vivo-specific or in vitro-specific enhancers were called as peaks with threefold increased or decreased RPKM values in vivo relative to in vitro, respectively. Enhancer data presentation. Heatmaps, aggregate plots and motif analysis were conducted using the Cistrome 35 galaxy instance. Heatmaps were created using the Heatmap tool, with 5,000 bp upstream and downstream, 200 bp step and saturation of 0.05. Aggregative plots were created using the aggregation plot tool, using a span of 3000 bp and resolution of 200 bp. Super-enhancers. In vivo and in vitro super-enhancers were identified using the dynamicEnhancer software (retrieved from https://github.com/BradnerLab/ pipeline). H3K27ac peaks identified as enhancers and separated by less than 12.5 kb were stitched together. All stitched peaks were then ranked by the density of H3K27ac minus input. Peaks higher than the inflection point on the density curve were designated super-enhancers. To call condition-specific super-enhancers, those from in vivo and in vitro conditions were merged and H3K27ac signals for all merged super-enhancers in each cell line were calculated. To be considered specific to in vivo or in vitro, super-enhancers had to be only called a super-enhancer in a single condition and had to have at least 1.5-fold change in H3K27ac signal between conditions. Genomic distribution of JMJD6. To call the genomic distribution of JMJD6 binding (Extended Data Fig. 8c ), each JMJD6 ChIP-seq binding peak was assigned to the underlying genomic element. Enhancers were defined as described earlier; areas surrounding TSSs were defined as ± 1 kb of all annotated TSSs in hg19, and other elements were defined by hg19 annotation. Each peak was assigned to a single element. In the cases in which a JMJD6 binding peak overlapped with two elements (for example, enhancer and intron), priority was assigned in the following order: enhancer; TSS ± 1 kb; 5′ UTR; 3′ UTR; exons; introns; and intergenic. Enrichment analysis of JMJD6 binding. To determine enrichment scores of JMJD6 peaks at a particular genomic element (for example, exons) ( Fig. 3d) , a null binding distribution of JMJD6 peaks for each element was generated by randomizing the peaks throughout the genome 1,000 times using bedtools shuffle. A z-score enrichment value at each genomic element was calculated using the actual number of JMJD6 peaks assigned to the genomic element compared to the average number of JMJD6 peaks and standard deviation from the null distribution. P values were obtained from this z-score using the standard normal distribution. JMJD6, enhancer and Pol II binding data presentation. Aggregate plots were constructed using the Cistrome 35 galaxy instance with the aggregation plot tool, using a span of 3,000 bp and resolution of 200 bp (Fig. 3g) . P values were calculated using Mann-Whitney U-test of RPKM values of Pol II at each set of loci. Calculation of pausing index. RPKM values were generated for all hg19 TSS loci (from 50 bp upstream to 200 bp downstream of TSS; − 50, + 200) and for the gene body of these transcripts (from 500 bp downstream of the TSS to the transcription termination site (TTS) (+ 500, TTS)) by first using the Galaxy 28 tool 'Count intervals in one file overlapping intervals in another file' to obtain total read counts for each TSS loci and gene body. Total Pol II reads were aligned to hg19 as above to create the necessary BAM file. RPKM values were then calculated using the formula: ((number of reads + 1)/(size of peak in bp/1,000))/number of aligned reads in millions.
Results were filtered as follows to ensure only high confidence calls were considered in the downstream analysis: transcripts < 750 bp were removed; transcripts overlapping any of the ENCODE blacklisted regions were removed; transcripts with Pol II density < 3.0 RPKM in the TSS region in either in vivo or in vitro condition were removed; transcripts with Pol II density < 0.4 RPKM in the body region in both in vivo and in vitro conditions were removed; for genes with multiple TSSs, only the transcript with the highest occupied TSS (by RPKM) was used; any gene that was not expressed at 0.25 FPKM by RNA-seq was removed; any transcript that overlapped other transcripts at this step was removed to avoid potential artefacts that occur by including reads from other TSS regions within the gene body region.
These filtering steps resulted in approximately 9,000 transcripts for GBM528 and around 8,000 transcripts for GBM3565. The pausing index was then calculated for each transcript using the formula: pausing index = (RPKM TSS)/(RPKM body). Individual gene knockdown studies by shRNA. For inducible shRNA knockdown studies of JMJD6 (Extended Data Fig. 9a-d) , LT3REVIR, a lentiviral version of the same inducible RT3REVIR delivery vector used in the primary screen, was used 4 . Glioblastoma cells were infected in culture, and Venus + cells harbouring the shRNA were selected by FACS. Cells were induced with doxycycline for 48 h and dsRED + cells expressing the shRNA were then selected by FACS. For in vitro studies, dsRED + cells were plated in 96-well plates on Geltrex LDEV-Free hESC-Qualified Reduced Growth Factor Basement Membrane Matrix (ThermoFisher) and maintained in media containing doxycycline. Cells were imaged using an Operetta High Content Imaging System (Perkin Elmer) on indicated days. The number of dsRED + cells for each well was calculated using Harmony High Content Image Analysis (Perkin Elmer). For in vivo studies, dsRED + cells were intracranially implanted into age-matched female NSG mice. Animals in the induced arm were maintained on doxycycline containing water (2 mg ml −1 doxycycline and 2% sucrose, Sigma) for the duration of the experiment. Mice in the uninduced control arm were maintained on water containing 2% sucrose. The induced shJMJD6 group contained five mice, while non-targeting (shREN) and uninduced shJMJD6 control groups each contained three mice, for a total of six control mice. All mice were monitored daily until development of neurological signs, at which time they were euthanized. shRNA sequences. JMJD6.1005: 5 ′ -T GC TG TT GA CA GT GA GC GA CA GC AA G A CG AA GC TA TT AC AT AG TG AA GC CA CA GA TG TA TG TA AT AG CTTCGTCT TGCTGGTGCCTACTGCCTCGGA-3′ ; REN.713: 5′ -T GC TG TT GA CA GT GA G C GC AG GA AT TA TA AT GC TT AT CT AT AG TG AA GC CA CA GA TG TA TA GA TA A G CATTATAATTCCTATGCCTACTGCCTCGGA-3′ . Validation studies of in vivo screen hits. We used the constitutive shRNA vector SGEP 4 , which is a constitutive version of the lentiviral vector used above. It allows for puromycin selection and has a constitutive GFP fluorescent reporter. For validation of 9 primary screen hits (Extended Data Fig. 3e-h) , including the positive control, patient-derived glioblastoma GBM528 cells were transduced with individual shRNAs targeting primary screen hits, or 2 independent negative controls (totalling 11 independent transduced populations, each transduced with a single shRNA). Infected populations of GBM528 cells were selected by 1 μ g ml −1 puromycin for 3 days and immediately implanted intracranially into age-matched female NSG mice; 4 mice were used for each experimental and control group. All mice were monitored daily until development of neurological signs, at which time they were euthanized.
In parallel, we conducted more in-depth validation of a top scoring transcription elongation factor in the primary screen, DOT1L, as well as another top screen hit that was not a transcription elongation factor, DPY30 (Fig. 4c, d and Extended Data Fig. 9i-x) . We used the top two scoring shRNAs from the screen for each gene and used three independent glioblastoma models, GBM3565, GBM528 and GBMcw1919. As above, we transduced cells with shRNAs targeting DOT1L, DPY30 or a non-targeting shRNA. Infected populations were selected by 1 μ g ml −1 puromycin for 5 days and knockdown of target was confirmed by qRT-PCR. To determine the effect of target knockdown on cells in vitro and in vivo, the same populations of cells collected at the same time point were used in in vitro proliferation assays and for in vivo survival studies in intracranial PDX models. For in vitro studies, cells were plated in 96-well plates on Geltrex as above and maintained in standard serum-free media. Cell proliferation was measured using Cell-Titer Glow (Promega). For in vivo studies, cells were implanted intracranially into age-matched NSG mice. All mice were monitored daily until development of neurological signs, at which time they were euthanized.
shRNA sequences: D PY 30 .0 0786: 5′-T GC TG TT GA CA GT GA GC GA CA GA AA AG TC AT CA AA GC AG AT AG TG AA GC CA CA GA TG TA TC TG CT TT GATGACT TTTCTGCTGCCTACTGCCTCGGA-3′; DPY30.00781: 5 ′-T GC TG TT GA CA GT G A GC GC CA AC GT TG AG AG AA TA GT AG AT AG TG AA GC CA CA GA TG TA TC TA CT AT TCTCTCAACGTTGTTGCCTACTGCCTCGGA-3′; DOT1L.19417: 5′-T GC TG TT GA CA GT GA GC GA CG CG AG TT CA GG AA GT GG AT AT AG TG AA GC CA C A GA TG TA TA TC CA CT TCCTGAACTCGCGGTGCCTACTGCCTCGGA-3′; D O T 1L .0 0642: 5 ′-TGCTGTTGACAGTGAGCGCTCAGAATAAACAGTAGAAA CATAGTGAAGCCACAGATGTATGTTTCTACTGTTTATTCTGAATGCCTA CTGCCTCGGA-3′. CRISPR-mediated JMJD6-knockout studies. The CRISPR design tool from Broad Institute (http://portals.broadinstitute.org/gpp/public/analysis-tools/ sgrna-design) was used to design the guide RNA (gRNA). Oligonucleotides were purchased from Fisher, and annealed and cloned into LentiCRISPR v2 plasmid, which was a gift from F. Zhang (Addgene plasmid 52961). The oligonucleotides used were as follows: JMJD6.454: forward, 5′-CACCGTTAATTCCCTCAGGATAACG-3′ , reverse, 5′-AAACCGTTATCCTGAGGGAATTAAC-3′; JMJD6.712: forward, 5′-CACC GCTGCTGTCAAAGATGTAAAG-3′; reverse, 5′ -AAACCTTTACATCTT TGACAGCAGC-3′ . Experimental design for complete knockout in clonal populations. For complete knockout studies (Fig. 4a-c) , GBM528 cells were transduced with one of two independent CRISPR-Cas9 constructs targeting JMJD6 or a non-targeting control and selected for integration of the lentiviral construct by puromycin. Single cells were expanded in vitro to obtain clonal populations and knockout was confirmed by western blot (see details below). Two clonal populations per sgRNA were subjected to parallel in vitro proliferation assays and in vivo survival assays. For in vitro studies, cells were plated in 96-well plates on Geltrex as above and maintained in standard serum-free media. Cell proliferation was measured using AlamarBlue cell viability reagent (ThermoFisher). For in vivo studies, cells were intracranially implanted into age-matched female NSG mice. Five mice for each clone, or ten mice for each sgRNA construct were used. All mice were monitored daily until development of neurological signs, at which time they were euthanized. Experimental design for knockout in bulk populations without clonal selection. Owing to the knockout efficiency being extremely high in the experiment above, we used CRISPR-mediated knockout of JMJD6 on a population of cells without clonal selection to confirm our results in another PDX glioblastoma model (Extended Data Fig. 9e-g) . GBMcw1919 cells were transduced as above, selected by puromycin, subjected to western blot to confirm population based knockdown, and then assayed in vitro and in vivo as above. For in vivo survival studies, five agematched female NSG mice were used for each sgRNA construct. Western blotting for JMJD6 to determine knockout. Cells were collected and lysed in hypotonic buffer with non-ionic detergent (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.5% NP-40; 50 mM NaF with protease inhibitors), incubated on ice for 15 min, and cleared by centrifugation at 10,000g at 4 °C for 10 min. Protein concentration was determined using the Bradford assay (Bio-Rad Laboratories). Equal amounts of protein were mixed with reducing Laemmli loading buffer, boiled, and electrophoresed in NuPAGE Gels (ThermoFisher), and then transferred to PVDF membranes (Millipore). Blocking was performed for 30 min with 5% nonfat dry milk in TBS plus 0.1% Tween 20 (TBST) and blotting performed with primary JMJD6 antibody (Active Motif, 61494) for 16 h at 4 °C. Tissue processing, histology and imaging. Tissue processing for histological sections was performed as reported previously 36 . Primary antibodies used: GFP to stain for Venus (1:250; Aves Labs GFP-1020), mCherry to stain for dsRED (1:250; Abcam Ab167453) and human nuclear antigen to stain for human cells (1:250; NovusBio clone 235-1 NBP2-34525V3). Species-specific Alexa-Fluor-conjugated secondary antibodies were used for detection (1:500; ThermoFisher). Tissue microarray immunohistochemistry and analysis. In brief, de-identified tissue microarrays were constructed from gliomas after obtaining University of Kentucky Institutional Review Board Approval. Three 2-mm diameter cores per tumour were obtained, with each core embedded in a separate tissue microarray block. A total of 104 cases comprised the TMAs, including 9 nonneoplastic controls (cortical dysplasias), 9 grade II astrocytomas, 11 grade III astrocytomas, 12 anaplastic oligodendrogliomas, 16 grade II oligodendrogliomas, and 47 grade IV glioblastomas. Immunohistochemistry was performed for each core as described previously 37 , but using an antibody towards JMJD6 (Abcam, ab64575). In brief, each core was semi-quantified on a relative scale from 0 to 3, with 0 = negative and 3 = strongest. Results from all three cores were averaged together to produce a final score for a tumour. Results were plotted based on WHO grade and differences were calculated via Mann-Whitney-Wilcoxon test. Retrospective analysis of gene expression in human gliomas. Gene expression correlations across primary patient glioblastoma tumours, expression of individual genes or gene signatures in primary patient gliomas, and patient survival were determined through analysis of the Allen Institute Ivy GAP (http://glioblastoma. alleninstitute.org), the National Cancer Institute Repository for Molecular Brain Neoplasia Data (REMBRANDT, https://caintegrator.nci.nih.gov/rembrandt/), or the TCGA (https://tcga-data.nci.nih.gov/tcga/). Normalized Ivy GAP (http:// glioblastoma.alleninstitute.org) and REMBRANDT datasets were downloaded from GlioVis (http://gliovis.bioinfo.cnio.es/), and TCGA glioblastoma RNaseqV2 dataset was downloaded from the Broad Institute GDAC Firehose via the TCGA2STAT package on R 38 . Correlation analysis of gene expression and gene signature scores. We created a gene signature of the 55 genes upregulated in vivo more than 2.5-fold in both GBM528 and GBM3565 models ( Fig. 3a and Extended Data Fig. 7a-d) . Gene signature scores within Ivy GAP samples were analysed via single-sample GSEA on GenePattern and normalized as z-scores across all samples in the given dataset 16, 39 . Correlation between gene signature z-scores and median-centred gene expression was determined as Pearson coefficient (r) values. Associated FDR-adjusted P values were calculated using the Benjamini-Hochberg procedure. MatLab (MathWorks) was used to determine correlation values and P values.
Individual gene correlation with JMJD6. To test correlation of all genes with JMJD6 across glioblastoma tumours (Extended Data Fig. 7e ), TCGA RNaseqV2 data were downloaded and analysed using R (http://www.r-project.org). The function ggpairs, available through the GGally package, was used to generate plots and determine pairwise correlation coefficients (http://CRAN.R-project. org/package= GGally). All glioblastoma tumours in the TCGA with RNA-seq data available were used. Survival analysis. For gene expression changes, high and low groups were defined as above and below the median, respectively. Kaplan-Meier curves were generated and log-rank (Mantel-Cox) analysis was performed using GraphPadPrism software (GraphPad Software). Direct comparison of TCGA RNA-seq gene expression data to our RNA-seq data. To evaluate directly the expression/activity level of genes in an existing glioblastoma gene expression databases (Extended Data Fig. 5d, e ), we used the RNaseqV2 TCGA database of glioblastoma tumours that were characterized by mRNA sequencing. FPKM data for RNaseqV2 were downloaded from https:// gdc-portal.nci.nih.gov/. We compared this data to our mRNA sequencing data from both intracranial and culture conditions in two glioblastoma tumour models.
To compare values directly, we took the raw FPKM values from the 166 TCGA tumours and our data and quantile-normalized them together. We evaluated expression of the 55 genes that were upregulated in vivo in both GBM3565 and GBM528 or all genes. Statistical analysis. Analysis for each plot is listed in the figure legend and/or in corresponding methods above. In brief, all grouped data are presented as mean ± s.d. All box and whisker plots of expression data are presented as median (middle line of box) ± the 25 percentile (top and bottom line of box, respectively). P values presented are calculated by two-sided Mann-Whitney U-test. Kaplan-Meier curves were generated and log-rank (Mantel-Cox) analysis was performed to generate P values using GraphPadPrism software (GraphPad Software). Sample sizes for each experiment are given in corresponding figures and/or methods above. Sizes were chosen based on previous experience with given experiments, or in the case of retrospective analysis, all available samples were included. Data availability. The datasets generated during and analysed during the current study are included within the published manuscript (and Supplementary Information) or have been deposited in Gene Expression Omnibus (RNA-seq and ChIP-seq data) under accession number GSE74529. All other data are available from the corresponding authors upon reasonable request.
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Extended Data Figure 1 | shRNA delivery vector performance. a, Top, schematic of the RT3REVIR shRNA delivery vector. Middle, once integrated into cells, a constitutive PGK promoter drives Venusfluorescent reporter and rtTA through an IRES element, creating an allin-one inducible vector. Bottom, when doxycycline is introduced to cells, it binds to rtTA and drives activity of the third generation TET-inducible promoter. This drives the dsRED fluorescent reporter and shRNA expression. In addition, it drives higher rtTA transcription through the IRES element, creating a positive-feedback loop that increases rtTA expression in the cell resulting in higher expression of inducible elements. b, The inducible shRNA delivery vector displays almost no unintended induction. Representative FACS plots from the parallel screen of cells infected with RT3REVIR with and without doxycycline treatment in vitro (left) and in vivo (right). c, RT3REVIR robustly expresses shRNAs and depletes cells expressing cell-lethal shRNAs in a competitive proliferation assay. Left, representative FACS plots over time of cells infected with a positive control shRNA against RPA3 and induced. Right, quantification of fluorescent cells in the representative competitive proliferation assay. Empty denotes cells with vector that had no shRNA; REN.713 denotes cells with vector containing negative-control shRNA targeting the Renilla protein. The percentage of cells actively expressing the shRNA within the total infected population from a single dish is shown.
Extended Data Figure 4 | Independent models confirm stimuluscontrolled and stress response programs upregulated in vivo and in primary tumours. a, b, Genes with an average expression change of more than 2.5-fold between conditions in GBM528 (a) and GBM3565 (b) cells, as determined by RNA-seq. GBM528 heatmap associated with Fig. 2b, c.  c, d , Cellular programs enriched by GSEA in cells grown in each condition. c, Representation of all enriched programs in vitro and in vivo using Enrichment Map 17 . d, Example GSEA enrichment plots for cells grown in vitro and in vivo. FDR values calculated by GSEA software. d-g, As in b-d, GSEA was performed using data generated from two independent models by Lee and colleagues 15 on cells grown in vitro versus in vivo intracranial xenograft tumours (e, g), or in vitro versus the primary glioblastoma from which the cells were derived (f, h). Cellular programs enriched in cells grown in each condition are presented using Enrichment Map. FDR values calculated by GSEA software.
Extended Data Figure 7 | Prioritization of JMJD6 as lead target. a, Top, expression across all Ivy GAP samples of gene signature of 55 genes upregulated in vivo in both PDX models. Middle, elongation factor hits. Bottom, corresponding histological tumour structure and TCGA molecular subtype of each sample represented. The signature and JMJD6 expression is highest in hypoxic regions, which also corresponds to more mesenchymal-like regions of the tumour. b, Expression correlation dot plot for JMJD6 data represented in a. c, d, Expression correlation of each elongation factor hit with gene signature of 55 genes upregulated in vivo in both PDX models across all REMBRANDT (c) and TCGA (d) glioblastoma tumours (bulk tumour expression. Ivy GAP data in a and Fig. 3a is microenvironment-specific expression. P value (a-d) by FDR-adjusted Benjamini-Hochberg procedure. e, JMJD6 mRNA-seq correlation with each gene across TCGA glioblastoma tumours. f, Example plots from GSEA using the gene correlations in e and a pre-rank list. g, Representative images from tissue microarray analysis of JMJD6 protein expression in Fig. 3c . h, Primary screen results for the four shRNAs targeting JMJD6. Only two out of the four shRNAs were represented in the library at appreciable levels, and both led to a RIGER depletion score of greater than 2. Values are median RPM ± s.d. of three biological replicates for induced populations and two biological replicates for the uninduced population.
